Evolving considerations in the design and interpretation of phase I trials investigating gemcitabine based chemoradiotherapy regimens.
McGinn
Cornelius J
CJ
Department of Radiation Oncology, University of Michigan, Ann Arbor 48109-0010, USA.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012107:Research Design; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine